Related Experiment Videos
CYP2A6 genetic variation and dexmedetomidine disposition
Utkarsh Kohli1, Pratik Pandharipande, Mordechai Muszkat
1Departments of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA.
European Journal of Clinical Pharmacology
|January 25, 2012
Summary
Genetic variations in Cytochrome P450 2A6 (CYP2A6) do not significantly impact dexmedetomidine clearance in intensive care unit (ICU) patients. This suggests CYP2A6 genotype is not a key factor in dexmedetomidine dosing variability.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Intensive Care Medicine
Background:
- Dexmedetomidine is widely used for sedation in ICUs, but dose requirements vary significantly between individuals.
- Cytochrome P450 2A6 (CYP2A6) is a key enzyme in dexmedetomidine metabolism.
- Genetic polymorphisms in CYP2A6 are known to influence the clearance of other drugs.
Purpose of the Study:
- To investigate whether variations in CYP2A6 genotypes affect the disposition and clearance of dexmedetomidine in critically ill patients.
- To determine if CYP2A6 genetic variability explains interindividual differences in dexmedetomidine dose requirements.
Main Methods:
- Studied 43 ICU patients receiving dexmedetomidine infusions.
- Measured multiple plasma dexmedetomidine concentrations per patient.
- Genotyped 40 patients for common CYP2A6 alleles, categorizing them into normal, intermediate, and slow metabolizer groups.
Main Results:
- Dexmedetomidine clearance was estimated using a Bayesian hierarchical nonlinear mixture model.
- No statistically significant differences in dexmedetomidine clearance were observed between the different CYP2A6 metabolizer groups (normal, intermediate, slow).
Conclusions:
- CYP2A6 genetic variation does not appear to be a significant determinant of dexmedetomidine clearance in the ICU patient population.
- Other factors likely contribute more to the observed interindividual variability in dexmedetomidine requirements.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...